Navigation Links
Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
Date:6/16/2008

BOSTON, June 16 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc. (OTC Bulletin Board: VOQP), entitled, "Robust Pipeline of Niche' Cancer Therapies with Billion Dollar Upside."

This review is available at website: http://www.scimitarequity.com.

VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment and prevention of Hand-Foot Syndrome, a common side effect from certain chemotherapy treatments, and to treat dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B. Further information about VioQuest can be found at: http://www.vioquestpharm.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimita
'/>"/>

SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
2. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
3. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
4. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. bioMETRX, Inc. Initiates Integration of Personnel and Assets of Sequiam Corp.
7. Lorus initiates development program exploring novel route of administration for LOR-2040
8. SemBioSys initiates toxicology study for safflower-produced insulin
9. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
10. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Lake, MN (PRWEB) May 21, 2013 The ... trade show display solution for sales and marketing teams looking ... Displays describes the kit as “everything you’ll need to ... Fusion Fabric Display Kit comes with a number of displays ... all-around trade booth 20 feet by 20 feet in size. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Oven Industries ... with ramp/soak capabilities. The 5R6-900 benchtop controller has many ... device can be plugged into the wall as a ... supply. This distinctive detail makes the device unique, as ... The laboratory temperature controller can also be used universally, ...
(Date:5/20/2013)... 20, 2013  Dr. Gerald Zon ... research, recently launched a new blog in conjunction with ... zon.trilinkbiotech.com ), focuses on what,s trending in the field ... thought leaders, discussions of research presented at conferences and ... Dr. Zon (PhD Princeton University 1971) developed automated ...
(Date:5/20/2013)... CHAPEL HILL, N.C. , May 20, 2013 ... pharmaceutical company focused on developing differentiated antibiotics to ... bacterial infections, today announced that it presented data ... 2013) in Philadelphia demonstrating ... versus levofloxacin in Cempra,s prior Phase 2 clinical ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2New Laboratory Temperature Controller by Oven Industries 2Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2
... July 5, 2011 Cellectis bioresearch, a subsidiary ... customization, has received the "Most Innovative New Service ... Access service offering. TALENs(1) allow for customized gene ... powerful and now affordable new tool. This prize ...
... 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), a ... Laszlo Radvanyi, Ph.D., an Associate Professor in the ... University of Texas MD Anderson Cancer Center in ... Board.  MD Anderson is one of the world,s ...
... 5, 2011 Cord Blood America, Inc . (OTC ... entered into an agreement with Regence ( www.regence.com/index.jsp ) to ... its BlueCross and BlueShield plans in Idaho, Oregon, Utah and ... BlueShield (BCBS) licensee contracts. The partnership gives Regence ...
Cached Biology Technology:TALEN® Access by Cellectis Bioresearch Receives "Most Innovative New Service 2011" Award at Life Science Awards 2Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board 2Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board 3Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions 2
(Date:5/20/2013)... MINNEAPOLIS/ST. PAUL (MAY 20, 2013) University of Minnesota ... of Minnesota, in partnership with the University,s Brain Tumor ... peripheral nerve sheath tumors (MPNST) that allow them to ... of cancer. , The research was published this week ... the Sleeping Beauty transposon method, researchers in the lab ...
(Date:5/20/2013)... The Amazon rain forest, popularly known as the lungs of ... use carbon dioxide from the air to grow parts that ... away by the region,s plentiful rainfall. , Until recently ... the Amazon River and ended up deep in the ocean. ... exhale huge amounts of carbon dioxide though left open ...
(Date:5/20/2013)... - A National Science Foundation (NSF) planning grant will ... (CARD), a joint program of the University of Illinois ... Mass. , "CARD will be devoted to research in ... agricultural products; forestry and paper products; chemical products; textiles; ... professor of food science and human nutrition and the ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3NSF approves planning grant for Center for Advanced Research in Drying 2
... , A series of papers published this month on ecological ... by the University of Colorado Boulder in the high mountains ... seasonal snow and ice are the most sensitive to changes ... April issue of the journal BioScience. The papers were ...
... Ga. Soldiers in war zones and farmers tending their ... impact their nerves. In large doses these agents, called ... can also produce chronic disabilities such as problems with learning ... Terry Jr., pharmacologist at the Medical College of Georgia at ...
... Clean drinking water and basic sanitation are human rights. ... have no access to drinking water and some 2.6 ... also an important economic factor: Today, agricultural and manufacturing ... this precious commodity. And the demand for water continues ...
Cached Biology News:CU research shows warming climate threatens ecology at mountain research site west of Boulder 2CU research shows warming climate threatens ecology at mountain research site west of Boulder 3Effect of chronic exposure to chemicals used as weapons, pesticides under study 2Effect of chronic exposure to chemicals used as weapons, pesticides under study 3Use less water, producing energy and fertilizer at the same time 2Use less water, producing energy and fertilizer at the same time 3
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... DNA Polymerase with a proprietary thermostable proofreading ... than standard Taq DNA polymerase, Double the ... DNA templates >20kb, Concentration: 5U/ul, Applications: high ... and mutagenesis We are part of Thermo ...
... EnzChek Lysozyme Assay Kit (E-22013) provides,researchers ... levels of lysozyme,activity in solution. This ... to 20 U/mL (Figure 1). The ... cell,walls, which are labeled to such ...
... based on measurenment of enzyme activity of ... microtiter plate. The procedure includes two incubation ... 2nd enzyme reaction) separated by a ... the determination of human enzymaticaly active TRAP ...
Biology Products: